Systematic analysis of host immunological pressure on the envelope gene of human immunodeficiency virus type 1 by an immunobioinformatics approach

Current HIV Research

Volumn 6, Issue 4, 2008, Pages 370-379

  Liang, Binhua ^a,d   Luo, Ma ^a   Ball, T Blake ^a   Yao, Xiaojian ^a   van Domselaar, Gary ^a,b   Cuff, Wilfred R ^b   Cheang, Mary ^a   Jones, Steven J M ^a,c   Plummer, Francis A ^a,b,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d NONE   (Canada)

Author keywords

Envelope; Host immune responses; Human immunodeficiency virus type 1; Positive selection; Vaccine

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROTEASOME; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; BIOINFORMATICS; CLADISTICS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENE SEQUENCE; GENE TARGETING; GENETIC SELECTION; HELPER CELL; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN DEGRADATION; QUASI EXPERIMENTAL STUDY; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SEQUENCE DATABASE; TIME;

AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES, T-LYMPHOCYTE; EVOLUTION, MOLECULAR; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SELECTION (GENETICS); T-LYMPHOCYTES, CYTOTOXIC;

EID: 52449109757     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785132554     Document Type: Review

References (77)

1. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5: 233-236.
2. Desrosiers RC. Prospects for an AIDS vaccine. Nat Med 2004; 10: 221-223.
3. Garber DA,Feinberg MB. AIDS vaccine development: the long and winding road. AIDS Rev 2003; 5: 131-9.
4. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24: 227-255.
5. da Silva J. The evolutionary adaptation of HIV-1 to specific immunity. Curr HIV Res 2003; 1: 363-71.
6. Frost SD, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102: 18514-9.
7. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296: 1439-43.
8. Ross HA, Rodrigo AG. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol 2002; 76: 11715-20.
9. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-312.
10. Mohabatkar H, Kar SK. Prediction of exposed domains of envelope glycoprotein in Indian HIV-1 isolates and experimental confirmation of their inummogenicity in humans. Braz J Med Biol Res 2004; 37: 675-681.
11. Bonhoeffer S, Holmes EC,Nowak MA. Causes of HIV diversity. Nature 1995; 376: 125.
12. Dulioust A, Paulous S, Guillemot L, Delavalle AM, Boue F, Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol 1999; 73: 850-54.
13. Leslie A, Kavanagh D, Honeyborne I, et al. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 2005; 201: 891-902.
14. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76: 8757-68.
15. Yamaguchi-Kabata Y, Yamashita M, Ohkura S, Hayami M, Miura T. Linkage of amino acid variation and evolution of human immunodeficiency virus type 1 gp120 envelope glycoprotein (subtype B) with usage of the second receptor. J Mol Evol 2004; 58: 333-40.
16. Choisy M, Woelk CH, Guegan JF,Robertson DL. Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J Virol 2004; 78: 1962-70.
17. Travers SA, O'Connell MJ, McCormack GP, McInerney JO. Evidence for heterogeneous selective pressures in the evolution of the env gene in different human immunodeficiency virus type 1 subtypes. J Virol 2005; 79: 1836-41.
18. Frost SD, Gunthard HF, Wong JK, Havlir D, Richman DD, Leigh Brown AJ. Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. Virology 2001; 284:250-258.
19. Zanotto PM, Kallas EG, de Souza RF, Holmes EC. Genealogical evidence for positive selection in the nef gene of HIV-1. Genetics 1999; 153: 1077-89.
20. Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94: 1890-5.
21. Yang W, Bielawski JP, Yang Z. Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J Mol Evol 2003; 57: 212-21.
22. Chen L, Perlina A, Lee CJ. Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. J Virol 2004; 78: 3722-32.
23. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet 2004; 5: 52-61.
24. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-9.
25. da Silva J,Hughes AL. Molecular phylogenetic evidence of cytotoxic T lymphocyte (CTL) selection on human immunodeficiency virus type 1 (HIV-1). Mol Biol Evol 1999; 16: 1420-2.
26. Zimbwa P, Milicic A, Frater J, et al. Precise Identification of an Hiv-1 Antigen Processing Mutant. J Virol 2006; 81: 2031-8.
27. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66: 3183-7.
28. Edwards CT, Holmes EC, Wilson DJ, et al. Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol 2006; 6:28.
29. Yang Z, Nielsen R, Goldman N,Pedersen AM. Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 2000; 155: 431-449.
30. Stewart JJ, Watts P,Litwin S. An algorithm for mapping positively selected members of quasispecies-type viruses. BMC Bioinformatics 2001; 2: 1.
31. Frost SD, Liu Y, Pond SL, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005; 79: 6523-7.
32. Piontkivska H,Hughes AL. Patterns of sequence evolution at epitopes for host antibodies and cytotoxic T-lymphocytes in human immunodeficiency virus type 1. Virus Res 2006; 116: 98-105.
33. Herbeck JT, Nickle DC, Learn GH, et al. Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol 2006; 80: 1637-44.
34. Liang B, Luo M, Ball TB, Plummer FA. QUASI analysis of the HIV-1 envelope sequences in the Los Alamos National Laboratory HIV sequence database: pattern and distribution of positive selection sites and their frequencies over years. Biochem Cell Biol 2007; 85: 259-64.
35. de Oliveira T, Salemi M, Gordon M, et al. Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design? Genetics 2004; 167: 1047-58.
36. Huelsenbeck JP, Ronquist F, Nielsen R, Bollback JP. Bayesian inference of phylogeny and its impact on evolutionary biology. Science 2001; 294: 2310-2314.
37. Pond SL, Frost SD, Grossman Z, Gravenor MB, Richman DD,Brown AJ. Adaptation to different human populations by HIV-1 revealed by condon-based analyses. PLoS Comput Biol 2006; 2: e62.
38. Suzuki Y, Gojobori T. A method for detecting positive selection at single amino acid sites. Mol Biol Evol 1999; 16: 1315-28.
39. Yang Z. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci 1997; 13: 555-6.
40. Peters HO, Mendoza MG, Capina RE, et al. An Integrative Bioinformatic Approach in Studying Escape Mutations in HIV-1 gag in the Pumwani Sex Worker Cohort. J Virol 2008; 82: 1980-92.
41. Nicole Frahm CB. Optimal CTL Epitope Identification in HIV Clade B and Non-Clade B Infection. HIV Molecular Immunology 2005.
42. Stephens HA. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol 2005; 26: 41-7.
43. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
44. Nielsen M, Lundegaard C, Lund O, Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005; 57: 33-41.
45. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354-60.
46. Liu C, Carrington M, Kaslow RA, et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187: 1404-10.
47. Propato A, Schiaffella E, Vicenzi E, et al. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum Immunol 2001; 62: 561-76.
48. Gao X, Bashirova A, Iversen AK, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11: 1290-2.
49. Scherer A, Frater J, Oxenius A, et al. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci USA 2004; 101: 12266-70.
50. Trachtenberg E, Korber B, Sollars C, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9: 928-35.
51. Geels MJ, Dubey SA, Anderson K, et al. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol 2005; 79: 11247-58.
52. Keating SM, Bollinger RC, Quinn TC, Jackson JB, Carruth LM. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays. AIDS Res Hum Retroviruses 2002; 18: 1067-79.
53. Wainberg MA. HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004; 18(Suppl 3): S63-8.
54. McKinnon LR, Ball TB, Kimani J, et al. Cross-clade CD8(+) T-cell responses with a preference for the predominant circulating clade. J Acquir Immune Defic Syndr 2005; 40: 245-9.
55. Slobod KS, Coleclough C, Brown SA, et al. Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary? AIDS Res Ther 2005; 2:3.
56. Mullins JI, Nickle DC, Heath L, Rodrigo AG, Learn GH. Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines 2004; 3: S151-9.
57. Binley JM, Wyatt R, Desjardins E, et al. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120. AIDS Res Hum Retroviruses 1998; 14: 191-8.
58. Maksiutov AZ, Bachinskii AG, Bazhan SI. [Searching for local similarities between HIV-1 and human proteins. Application to vaccines]. Mol Biol (Mosk) 2002; 36: 447-59.
59. Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996; 70: 1863-72.
60. Moore JP, Willey RL, Lewis GK, Robinson J, Sodroski J. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp 120 surface glycoprotein of human immunodeficiency virus type 1. J Virol 1994; 68: 6836-47.
61. Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003; 77: 5889-901.
62. Yang X, Farzan M, Wyatt R, Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2000; 74: 5716-25.
63. Yamaguchi-Kabata Y,Gojobori T. Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes. J Virol 2000; 74: 4335-4350.
64. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265: 10373-82.
65. Li Y, Luo L, Rasool N, Kang CY. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 1993; 67: 584-8.
66. Huang X, Barchi JJ, Jr., Lung FD, et al. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Biochemistry (Mosc) 1997; 36: 10846-56.
67. Louwagie J, Janssens W, Mascola J, et al. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol 1995; 69: 263-71.
68. Scanlan CN, Pantophlet R, Wormald MR, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alphal→2 mannose residues on the outer face of gp120. J Virol 2002; 76: 7306-21.
69. Sanders RW, Venturi M, Schiffner L, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76: 7293-305.
70. Imami N, Hardy G, Pires A, Burton C, Sullivan A, Gotch F. Detection and quantification of HIV-1 specific CD4 helper and CD8 cytotoxic cells: their role in HIV-1-infected individuals and vaccine recipients. HIV Med 2001; 2: 146-53.
71. Jansen CA, van Baarle D, Miedema F. HIV-specific CD4+ T cells and viremia: who's in control? Trends Immunol 2006; 27: 119-24.
72. Anisimova M, Nielsen R,Yang Z. Effect of recombination on the accuracy of the likelihood method for detecting positive selection at amino acid sites. Genetics 2003; 164: 1229-36.
73. Shriner D, Nickle DC, Jensen MA, Mullins JI. Potential impact of recombination on sitewise approaches for detecting positive natural selection. Genet Res 2003; 81: 15-21.
74. Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004; 3: S161-8.
75. Nickle DC, Jensen MA, Gottlieb GS, et al. Consensus and ancestral state HIV vaccines. Science 2003; 299: 1515-1518.
76. Hager-Braun C, Katinger H, Torner KB. The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen. J Immunol 2006; 176: 7471-81.
77. Stanhope PE, Liu AY, Pavlat W, Pitha PM, Clements ML, Siliciano RE. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J Immunol 1993; 150: 4672-86.